奇正藏药(002287) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥253,751,327.31, representing an increase of 11.78% compared to ¥227,009,592.79 in the same period last year[11]. - The net profit attributable to shareholders for Q1 2019 was ¥84,775,457.81, up by 9.98% from ¥77,080,535.58 in the previous year[11]. - Basic earnings per share for Q1 2019 were ¥0.2088, reflecting a growth of 9.95% from ¥0.1899 in the previous year[11]. - The company reported a net profit for the current period of ¥84,479,612.85, representing a growth of 10% from ¥76,867,042.08 in the previous period[63]. - The net profit for the current period is 57,878,122.53, an increase from 47,599,629.39 in the previous period, representing a growth of approximately 21.4%[71]. - The total comprehensive income for the current period is 57,878,122.53, compared to 47,599,629.39 in the previous period, indicating a year-over-year increase of about 21.4%[73]. Cash Flow - The net cash flow from operating activities was negative at -¥76,654,708.01, a decrease of 171.43% compared to ¥107,313,068.85 in the same period last year[11]. - The cash flow from operating activities shows a net outflow of -76,654,708.01, a significant decrease from a net inflow of 107,313,068.85 in the previous period[77]. - Cash inflow from investment activities is 143,566,945.31, while cash outflow is 313,213,612.95, resulting in a net cash flow from investment activities of -169,646,667.64[80]. - The cash flow from financing activities shows a net inflow of 482,390.00, contrasting with a net outflow of 163,883,014.89 in the previous period[80]. - The company’s cash flow from operating activities remains strong, supporting ongoing investments in new product development and market expansion strategies[60]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,344,447,385.37, an increase of 1.37% from ¥2,312,773,222.44 at the end of the previous year[11]. - Total liabilities increased by 111.49% to ¥18,766,677.12 from ¥8,873,757.85, primarily due to higher payables for raw materials and project payments[27]. - Total liabilities decreased to ¥346,888,940.04 from ¥354,866,576.20, indicating a reduction of approximately 2%[59]. - The total assets and liabilities combined reached ¥2,319,335,007.14, an increase from ¥2,268,709,912.31, showing a growth of 2.2%[59]. - The total cash and cash equivalents at the end of the period is 149,692,537.95, down from 254,125,773.27 at the beginning of the period[80]. Investments and Income - The company reported an investment income of ¥6,817,608.32 from financial products during the reporting period[11]. - Investment income surged by 2133.68% to ¥6,817,608.32 from ¥305,219.18, driven by increased returns from financial products[27]. - The company reported a significant increase in cash paid for purchasing goods and services, totaling $24,341,009.16, compared to $23,693,239.51 previously[83]. Expenses - Research and development expenses rose by 47.26% to ¥5,824,296.60 from ¥3,955,244.77, reflecting increased spending on technology research[27]. - The company reported a 91.40% increase in management expenses to ¥20,807,555.90 from ¥10,871,374.41, driven by higher depreciation, employee compensation, and consulting fees[27]. - The company paid 71,063,631.32 in cash to employees, an increase from 56,852,863.75 in the previous period, representing a growth of about 24.9%[77]. Shareholder Information - The top shareholder, Gansu Qizheng Industrial Group Co., Ltd., holds 69.16% of the shares, totaling 280,780,000 shares[16]. - The company did not engage in any repurchase transactions during the reporting period[21].